A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

NCT05442047 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions

DRUG: NNC6019-0001
DRUG: Placebo (NNC6019-0001)

Sponsor

Novo Nordisk A/S